152 related articles for article (PubMed ID: 26096855)
1. Regulation of Cell- and Tissue-Based Therapeutic Products in Singapore.
Kellathur SN
Tissue Eng Part A; 2015 Dec; 21(23-24):2802-5. PubMed ID: 26096855
[TBL] [Abstract][Full Text] [Related]
2. Regulatory Oversight of Cell- and Tissue-Based Therapeutic Products and Gene Therapy Products in Singapore.
Goh CW; Kellathur SN; Ong LL; Wu X
Adv Exp Med Biol; 2015; 871():195-212. PubMed ID: 26374220
[TBL] [Abstract][Full Text] [Related]
3. Clinical Translation of Cell Therapy, Tissue Engineering, and Regenerative Medicine Product in Malaysia and Its Regulatory Policy.
Bt Hj Idrus R; Abas A; Ab Rahim F; Saim AB
Tissue Eng Part A; 2015 Dec; 21(23-24):2812-6. PubMed ID: 26192075
[TBL] [Abstract][Full Text] [Related]
4. Regulation Policy on Cell- and Tissue-Based Therapy Products in Korea.
Lim JO
Tissue Eng Part A; 2015 Dec; 21(23-24):2791-6. PubMed ID: 25759938
[TBL] [Abstract][Full Text] [Related]
5. Regulation of Regenerative Medicine Products.
Gee AP
Adv Exp Med Biol; 2018; 1098():189-198. PubMed ID: 30238372
[TBL] [Abstract][Full Text] [Related]
6. Regulation Policy for Cell and Tissue Therapies in Australia.
Sturm M
Tissue Eng Part A; 2015 Dec; 21(23-24):2797-801. PubMed ID: 26096750
[TBL] [Abstract][Full Text] [Related]
7. [Regulatory requirements regarding cell-based medicinal products for human and veterinary use - a comparison].
Kuhlmann-Gottke J; Duchow K
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2015 Nov; 58(11-12):1299-305. PubMed ID: 26369765
[TBL] [Abstract][Full Text] [Related]
8. Cell and tissue therapy regulation: worldwide status and harmonization.
Kellathur SN; Lou HX
Biologicals; 2012 May; 40(3):222-4. PubMed ID: 22374355
[TBL] [Abstract][Full Text] [Related]
9. [International approaches to the regulation of cell therapy products].
Piatigorskaia NV; Tulina MA; Aladysheva ZhI; Beregovykh VV
Vestn Ross Akad Med Nauk; 2013; (8):4-8. PubMed ID: 24340637
[TBL] [Abstract][Full Text] [Related]
10. Premarket Regulation of Tissue Engineered Medical Products in China.
Wang C; Wang A; Feng X; Ke L; Huang Y; Han Q; Sun X; Yang Z
Tissue Eng Part A; 2015 Dec; 21(23-24):2806-11. PubMed ID: 26529310
[TBL] [Abstract][Full Text] [Related]
11. [Supervision, administration and standard research related to tissue engineered medical products].
Xi TF; Chen L; Zhao P
Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi; 2003 Nov; 17(6):480-7. PubMed ID: 14663949
[TBL] [Abstract][Full Text] [Related]
12. European regulation for therapeutic use of stem cells.
Ferry N
Biomed Mater Eng; 2017; 28(s1):S3-S7. PubMed ID: 28372273
[TBL] [Abstract][Full Text] [Related]
13. Regulatory and microbiological safety issues surrounding cell and tissue-engineering products.
Galbraith DN
Biotechnol Appl Biochem; 2004 Aug; 40(Pt 1):35-9. PubMed ID: 15270705
[TBL] [Abstract][Full Text] [Related]
14. Four Food and Drug Administration draft guidance documents and the REGROW Act: A litmus test for future changes in human cell- and tissue-based products regulatory policy in the United States?
Yano K; Speidel AT; Yamato M
J Tissue Eng Regen Med; 2018 Jul; 12(7):1579-1593. PubMed ID: 29702746
[TBL] [Abstract][Full Text] [Related]
15. [Clinical trials with advanced therapy medicinal products].
Schüssler-Lenz M; Schneider CK
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2010 Jan; 53(1):68-74. PubMed ID: 20011994
[TBL] [Abstract][Full Text] [Related]
16. Raising the standard: changes to the Australian Code of Good Manufacturing Practice (cGMP) for human blood and blood components, human tissues and human cellular therapy products.
Wright C; Velickovic Z; Brown R; Larsen S; Macpherson JL; Gibson J; Rasko JE
Pathology; 2014 Apr; 46(3):177-83. PubMed ID: 24614714
[TBL] [Abstract][Full Text] [Related]
17. European Medicines Agency, CAT Secretariat & US Food and Drug Administration.
Regen Med; 2011 Nov; 6(6 Suppl):90-6. PubMed ID: 21999268
[TBL] [Abstract][Full Text] [Related]
18. [Safety monitoring of cell-based medicinal products (CBMPs)].
Funk MB; Frech M; Spranger R; Keller-Stanislawski B
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2015 Nov; 58(11-12):1239-46. PubMed ID: 26391098
[TBL] [Abstract][Full Text] [Related]
19. [Specific aspects for virus safety of raw materials for cellular-based medicinal products].
Stühler A; Blümel J
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2015 Nov; 58(11-12):1233-8. PubMed ID: 26383536
[TBL] [Abstract][Full Text] [Related]
20. Regulatory Oversight of Cell, Tissue, and Gene Therapy Products in Singapore.
Ong LL
Adv Exp Med Biol; 2023; 1430():197-210. PubMed ID: 37526849
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
